resveratrol has been researched along with cladribine in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
Bednarek, A; Fabianowska-Majewska, K; Rudnicka, K; Stefanska, B | 1 |
Chocholska, S; Dmoszynska, A; Halicka, D; Klimek, P; Kowal, M; Podhorecka, M | 1 |
3 other study(ies) available for resveratrol and cladribine
Article | Year |
---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Hypomethylation and induction of retinoic acid receptor beta 2 by concurrent action of adenosine analogues and natural compounds in breast cancer cells.
Topics: Adenosine; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cholecalciferol; Cladribine; DNA Methylation; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Promoter Regions, Genetic; Receptors, Retinoic Acid; Resveratrol; Stilbenes; Transcriptional Activation; Tretinoin; Vidarabine | 2010 |
Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia.
Topics: ADP-ribosyl Cyclase 1; Adult; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; bcl-2-Associated X Protein; Caspase 3; Cell Cycle Proteins; Cladribine; DNA-Binding Proteins; Drug Therapy, Combination; Enzyme Activation; Histones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Membrane Glycoproteins; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Resveratrol; Stilbenes; Tumor Suppressor Proteins; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2011 |